Mach7 Technologies (M7T) Status update summary
Event summary combining transcript, slides, and related documents.
Status update summary
9 Jul, 2026Strategic reset and financial transformation
Achieved positive operating cash flow in Q2 and Q3, maintaining zero debt and a strong balance sheet.
Cost base reduced by 6% through disciplined management and operational overhaul.
Shifted focus from lumpy capital deals to a recurring revenue model, strengthening financial predictability.
Leadership team revitalized, emphasizing cost discipline and commercial execution.
Growth now prioritized following a reset year focused on internal restructuring.
Market opportunity and industry trends
Enterprise imaging market projected to double by 2030, reaching AUD 4 billion.
Increasing demand for AI-enabled imaging and digital pathology due to radiologist shortages and rising imaging volumes.
Open APIs, EMR interoperability, and hybrid cloud/on-prem solutions are key industry trends.
Security and compliance are critical, with healthcare organizations facing heightened cyber threats.
Modular solutions allow customers to modernize without high-risk system replacements.
Product innovation and differentiation
Vendor-neutral archive (VNA) ingests images from any source, supporting true data independence.
eUnity Enterprise Diagnostic Viewer offers zero-footprint, FDA-approved access to diverse image types.
Flamingo Architecture enables modular upgrades, validated with early adopter customers and expanding in FY27.
Differentiators include data independence, security, price-to-performance value, and customer-centric innovation.
Customer engagement drives product development, with direct developer-customer collaboration.
Latest events from Mach7 Technologies
- Revenue up 33%, recurring revenue covers 80% of OpEx, and positive EBITDA with share buy-back announced.M7T
H1 20258 Jul 2026 - Recurring revenue and cash flow surged, with FY25 growth guidance and buyback reaffirmed.M7T
Q2 2025 TU8 Jul 2026 - Record recurring revenue and sales orders drive positive cash flow and strong FY25 outlook.M7T
H2 202429 May 2026 - 16% revenue growth, recurring revenue covers 80% of OPEX, and cash flow is positive.M7T
H2 202529 May 2026 - Revenue fell 23% year-over-year, but recurring revenue and cost discipline support future growth.M7T
H1 202629 May 2026 - Q3 FY26 saw positive cash flow, ARR growth, and a strong cash position amid cost discipline.M7T
Q3 202624 Apr 2026 - Stable ARR, positive cash flow, and new product traction support a confident outlook.M7T
Q2 20263 Feb 2026 - Sales orders up 52%, recurring revenue and cash at record highs, subscription growth strong.M7T
Q4 2024 TU2 Feb 2026 - CARR and ARR rose in Q1 FY25, with strong cash reserves and reaffirmed growth guidance.M7T
Q1 2025 TU17 Jan 2026